FDA Approves Multi-Dose Vial of Trastuzumab Biosimilar

The FDA has approved a 420 mg multi-dose vial of trastuzumab-dttb (Ontruzant), a biosimilar referencing trastuzumab (Herceptin).

Source: CancerNetwork - March 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news